Overview
Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Status:
Recruiting
Recruiting
Trial end date:
2024-09-30
2024-09-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Aura Biosciences
Criteria
Inclusion Criteria:- Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)
- Have no evidence of metastatic disease confirmed by imaging
- Be treatment naïve for IL/CM
Exclusion Criteria:
- Have known contraindications or sensitivities to the study drug or laser
- Active ocular disease